Spartan Bioscience Announces First Rapid APOE Genetic Test to Accelerate Clinical Drug Trials for Alzheimer’s Disease
July 29th, 2016
Spartan Bioscience today announced the first rapid Apolipoprotein E (APOE) genetic test to identify mutations associated with increased risk of late-onset Alzheimer’s disease. The Spartan Cube test provides results in 30 minutes from a patient-friendly non-invasive cheek swab.
The Spartan Cube, the world’s smallest DNA-testing device, is the fastest way to identify patients to enroll in clinical trials or research studies based on their genetics. One-in-four people carry APOE genetic mutations that increase the risk of developing Alzheimer’s. These genetic carriers can be ideal clinical trial candidates, and the Cube can accelerate the identification and enrollment of these patients. For example, the Spartan Cube enables patient testing in doctors’ offices, walk-in clinics or even nursing homes.
Alzheimer’s disease affects more than five million patients in the United States. With an aging baby boomer population, this number will increase significantly, barring a medical breakthrough in treatment or prevention. By 2050, the number of people age 65 and older with Alzheimer's disease may nearly triple from 5.2 million to 13.8 million in the United States alone.